The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report from Grand View Research said that ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Both Fischel and La Bomba Pharmacies have asked their diabetic customers to schedule a free screening as part of a collaborative program where Ainnova will use its cutting-edge AI platform, Vision AI, ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Oracle Corp. (ORCL) shares jumped 13.3% after reporting fourth-quarter fiscal 2025 adjusted earnings per share of $1.70, surpassing the Zacks Consensus Estimate of $1.64. Shares of Alphabet Inc.

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...

COPENHAGEN] Novo Nordisk reclaimed its position as Europe’s most valuable public company, overtaking software developer SAP. Read more at The Business Times.